{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:29:17Z","timestamp":1784168957911,"version":"3.55.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Attention deficit hyperactivity disorder (ADHD) is quite common in the general pediatric population, Its incidence is thought to be even higher in the population of patients with congenital heart disease, especially in those patients with complex disease and who have had cardiac surgical interventions early in life. There has been controversy as to the safety of ADHD medications, especially in the latter population of patients. This compendium is meant to review the effects of the ADHD medications and the safety of these medications in patients with either known or undiagnosed congenital heart disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The concern with regard to the use of ADHD medications has been as a result of the reports of sudden unexpected deaths among patients taking stimulant drugs for ADHD. Therefore, the question of whether or not stimulant drugs increase the risk of adverse cardiovascular events has led to a discussion of the appropriate use of these drugs in patients with known cardiovascular disease, as well as a discussion as to the appropriate evaluation in order to identify undiagnosed \u2018at-risk\u2019 patients with congenital heart disease or arrhythmias. This article will review and amplify these discussions, as well as the conclusions that have come forth as a result of these discussions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Currently available data suggest that there is no evidence for serious adverse cardiovascular complications in children with known cardiovascular diseases including patients of congenital heart disease who are treated with stimulant medications. Despite this, if the patient does have known cardiac disease, or if the history and physical examination is suggestive of cardiac disease, it is suggested that consultation\/evaluation with a pediatric cardiologist occur. It is extremely unlikely that stimulant medications would be contraindicated in almost any condition that falls under this category. However, a few specific cardiac conditions might tailor the choice of the specific ADHD medication. Therefore the coordination of care between the primary care physician, the ADHD medication-prescribing physician, and the pediatric cardiologist may be very important in this circumstance.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000388","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T12:09:58Z","timestamp":1464955798000},"page":"607-612","source":"Crossref","is-referenced-by-count":15,"title":["Attention deficit hyperactivity disorder medications in children with heart disease"],"prefix":"10.1097","volume":"28","author":[{"given":"Stuart","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.cjca.2013.07.007","article-title":"Early repair of congenital heart disease associated with increased risk of ADHD symptoms","volume":"29","author":"Yamada","year":"2013","journal-title":"Can J Cardiol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1442-200X.2012.03711.x","article-title":"Prevalence of ADHD symptoms in patients with congenital heart disease","volume":"54","author":"Hansen","year":"2012","journal-title":"Pediatr Int"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"e759","DOI":"10.1542\/peds.2007-1066","article-title":"Inattention, hyperactivity and school performance in a population of school-aged children with complex congenital heart disease","volume":"12","author":"Shillingford","year":"2008","journal-title":"Pediatrics"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jpeds.2005.03.014","article-title":"Short-term and long-term cardiovascular effects of mixed amphetamine salts extended release in children","volume":"147","author":"Finding","year":"2005","journal-title":"J Pediatr"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00467-005-2051-1","article-title":"Effect of stimulants on 24 hour ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross over trial","volume":"21","author":"Samuels","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp068049","article-title":"ADHD drugs and cardiovascular risk","volume":"354","author":"Nissen","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-20230918","first-page":"16","article-title":"FDA Panel recommends black-box warning on ADHD stimulant medications","volume":"27","author":"Gorman","year":"2006","journal-title":"AAP News"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.pcl.2004.04.008","article-title":"Sudden death in children and adolescents: introduction and overview","volume":"51","author":"Berger","year":"2004","journal-title":"Pediatr Clin North Am"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1056\/NEJMoa1110212","article-title":"ADHD drugs and serious cardiovascular events in children and young adults","volume":"365","author":"Cooper","year":"2011","journal-title":"N Engl J Med"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1542\/peds.2010-3371","article-title":"Cardiovascular events and death in children exposed and unexposed to ADHD agents","volume":"127","author":"Schelleman","year":"2011","journal-title":"Pediatrics"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"e4627","DOI":"10.1136\/bmj.e4627","article-title":"Cardiovascular safety of ventral nervous system stimulants in children and adolescents: population-based cohort study","volume":"345","author":"Winterstein","year":"2012","journal-title":"BMJ"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1176\/appi.ajp.2009.09040472","article-title":"Sudden death and use of stimulant medications in youths","volume":"166","author":"Gould","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1542\/peds.105.5.1082","article-title":"Neurodevelopmental outcome and lifestyle assessment in school-aged and adolescent children with hypoplastic left heart syndrome","volume":"105","author":"Mahle","year":"2000","journal-title":"Pediatrics"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1542\/peds.2004-0227","article-title":"The effect of chronic and intermittent hypoxia on cognition in children: a review of the evidence","volume":"114","author":"Bass","year":"2004","journal-title":"Pediatrics"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0030-6665(05)70278-4","article-title":"Velocardiofacial syndrome","volume":"105","author":"Shprintzen","year":"2000","journal-title":"Otolaryngol Clin North Am"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4088\/JCP.v64n1004","article-title":"Methylphenidate treatment for attention deficit\/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study","volume":"64","author":"Gothelf","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.jcp.0000106223.36344.df","article-title":"Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention deficit\/hyperactivity disorder: results form one-year follow-up study","volume":"24","author":"Wilens","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.amjcard.2009.06.052","article-title":"Electrocardiographic screening in children with attention-deficit hyperactivity disorder","volume":"104","author":"Mahle","year":"2009","journal-title":"Am J Cardiol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archpediatrics.2010.278","article-title":"Impact of American Heart Association scientific statement on screening electrocardiograms and stimulant medications","volume":"165","author":"Thomas","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1161\/CIRCULATIONAHA.107.189473","article-title":"Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit disorder\/hyperactivity disorder: a scientific Statement from the American Heart Association Council on Cardiovascular Diseases in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing","volume":"117","author":"Vetter","year":"2008","journal-title":"Circulation"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1542\/peds.2008-1573","article-title":"Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit\/hyperactivity disorder","volume":"122","author":"Perrin","year":"2008","journal-title":"Pediatrics"},{"key":"R23-20230918","first-page":"36","article-title":"FDA preliminary report: safety of stimulant medications","volume":"5","author":"Stein","year":"2006","journal-title":"J Watch Pediatr Adolesc Med"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1542\/peds.2006-0942","article-title":"Stimulants and sudden death: what is a physician to do?","volume":"118","author":"Wilens","year":"2006","journal-title":"Pediatrics"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201610000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:00:57Z","timestamp":1695002457000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201610000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000388","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}